T

op of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with the delicious chocolate coconut blend for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Teva Pharmaceutical (TEVA) rejected a request from Israeli Prime Minister Benjamin Netanyahu to keep its manufacturing plant in Jerusalem running, Reuters says. The generic drug maker plans to cut debt by reducing its workforce by more than a quarter, or 14,000 jobs, including 1,700 in Israel, where a manufacturing site in Jerusalem will close. About 320 workers will lose their jobs in Jerusalem in 2018 and 500 would be laid off in 2019 when the plant shuts.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy